Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+.
Monoamine metabolites and amino acid concentration in cerebrospinal fluid (CSF) of 33 untreated patients with parkinsonian syndrome, and 20 control patients without specific neurological symptoms have been compared with those obtained in cerebrospinal fluid of rats intrastriatally lesioned with 1-methyl-4-phenylpyridinium ion (MPP+) and sham operated animals. Homovanillic acid content was found to be significantly lower in patients with severe parkinsonism (motor score of UPDRS > 24), but not in patients with mild symptoms (motor score < or = 24). A correlation between the loss of striatal dopamine and the decrease in cerebrospinal homovanillic acid has been established in rats treated with MPP+. The extrapolation of these results to those obtained from human patients could be important in assessing the degree of striatal dopamine loss shown by humans with parkinsonian syndrome at the moment of clinical diagnosis. No significant differences were found between the other monoamine metabolites analyzed and free amino acid content in human and rat CSF.
Espino
A
A
Department of Neurology, Hospital Prínceps d'Espanya, Spain.
Ambrosio
S
S
Bartrons
R
R
Bendahan
G
G
Calopa
M
M
D015655:1-Methyl-4-phenylpyridinium; D000368:Aged; D000596:Amino Acids / Q000134:cerebrospinal fluid*; D000818:Animals; D015306:Biogenic Monoamines / Q000134:cerebrospinal fluid / Q000378:metabolism*; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D010302:Parkinson Disease, Secondary / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000596:Amino Acids; D015306:Biogenic Monoamines; D015655:1-Methyl-4-phenylpyridinium; D006719:Homovanillic Acid